Fig. 7: Clinical outcomes associated with the expression of the IGSF9, PRDM16, and ALDH2 proteins in 86 patients with IMPC. | Nature Communications

Fig. 7: Clinical outcomes associated with the expression of the IGSF9, PRDM16, and ALDH2 proteins in 86 patients with IMPC.

From: Genomic alterations and evolution of cell clusters in metastatic invasive micropapillary carcinoma of the breast

Fig. 7

a–f Images of immunohistochemical staining for IGSF9, PRDM16, and ALDH2 in patients with IMPC (n = 86). The upper panel shows low expression of IGSF9, PRDM16, and ALDH2 in patients with IMPC; the lower panel shows high expression of the IGSF9, PRDM16, and ALDH2 proteins in patients with IMPC, ×400 magnification. g The association of IGSF9, PRDM16, and ALDH2 protein expression with OS and DFS. The upper panel shows OS, and the lower panel shows DFS, with patients with IMPC stratified by high and low protein expression. Log-rank test, two-sided. The P values for OS of IGSF9, PRDM16, and ALDH2 were 0.000, 0.004, and 0.004, respectively; the P values for DFS of IGSF9, PRDM16, and ALDH2 were 0.010, 0.003, and 0.001, respectively. P < 0.05 was considered to indicate statistical significance.

Back to article page